MTOR and subependymal giant cell astrocytoma: Everolimus is an inhibitor of the mammalian target of rapamycin (mTOR) and has been approved for the prevention of organ transplant rejection as well as for the treatment of subependymal giant cell astrocytoma, neuroendocrine tumors, renal cell carcinoma and breast cancer [3-8].